CRISPR Therapeutics AG 뉴스 - CRSP | 주식 나스닥

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones

-Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a...

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a...

Form 4 - Statement of changes in beneficial ownership of securities

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a...

Form 4 - Statement of changes in beneficial ownership of securities

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and...

Form 4 - Statement of changes in beneficial ownership of securities

jondoeuk 4 일 전

Anticipated 2025 milestones https://www.globenewswire.com/news-release/2025/01/13/3008308/0/en/CRISPR-Therapeutics-Highlights-Strategic-Priorities-and-Anticipated-2025-Milestones.html

👍️ 1

jondoeuk 4 일 전

Link to the webcast https://jpmorgan.metameetings.net/events/healthcare25/sessions/58421-crispr-therapeutics/webcast/general_signin?gpu_only=true&kiosk=true+%5Bjpmorgan.metameetings.net%5D

👍️ 1

jondoeuk 1 주 전

They will present at the 43rd Annual J.P. Morgan Healthcare Conference (Jan 14, at 2:15 PM PST).

The PR https://www.globenewswire.com/news-release/2024/12/09/2993974/0/en/CRISPR-Therapeutics-Presents-Data-at-the-2024-American-Society-of-Hematology-ASH-Annual-Meeting.html

Poster https://ir.crisprtx.com/static-files/12114290-21a6-4544-9cb7-de4fe2852e94

👍️0

PonkenPlonken 2 월 전

Neglected ugly duckling. $NTLA, $VERV & $CRBU now do trials outside of the US.... Maybe sentiment change is on the horizon -- see below

"The CBER director also apologized for “mistakes” in how the FDA handled early work for in vivo gene therapies, which “led to offshoring of some of the trials.”"
https://endpts.com/fda-vaccine-chief-peter-marks-pledges-to-stay-as-long-as-hes-welcome/#:~:text=The%20CBER%20director%20also%20apologized,%E2%80%9Cit%20is%20really%20important.%E2%80%9D

CHEAP CHEAP
SRPT and BMS announcing nice CRISPR deals with ARWR and PRME should help this too!

👍️0

jondoeuk 2 월 전

CTX130 data in R/R T-cell lymphomas (peripheral T-cell lymphoma or cutaneous T-cell lymphoma) https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00508-4/abstract

The ORR was 46.2%. Of those treated at DL3 and higher, the ORR was 51.6%.

👍️ 1

PonkenPlonken 2 월 전

so so so undervalued and misunderstood i believe...... frankly just cheap
https://x.com/RNAiAnalyst/status/1859876294487363651

👍️ 1

jondoeuk 2 월 전

They now have the ability to put in eight to nine edits. So it is a single cassette that expresses the CAR, can express a cytokine and has an shRNA-like approach to knock down genes. So there's no theoretical limit as to the number of edits, but there may be marginal utility beyond a certain point.

Hopefully, they look to improve donor selection, cell selection and manufacturing, as all could increase efficacy.

👍️ 1

jondoeuk 2 월 전

ASH abstract https://ash.confex.com/ash/2024/webprogram/Paper203563.html

👍️0

jondoeuk 2 월 전

Q3 business update and financial results https://www.globenewswire.com/news-release/2024/11/05/2974996/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2024-Financial-Results.html

OT: In this Dr. Urnov, PhD, laid out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies https://www.liebertpub.com/doi/10.1089/crispr.2024.0082

👍️ 1

TechandBio 4 월 전

CRSP will climb tremendously over the years.
SMMT went from $1.00-30.00+ this year cancer drug superior to Mercks Keytruda
ICCM company being over looked that kills cancers by freezing them 97% non recurrence rate for breast cancer after 5 years and superior data to lung cancer safe cryoblation is done in less than hour.
https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

👍️0

Monksdream 4 월 전

Buy range again thanks a bunch

👍️0

Monksdream 4 월 전

Buy range again thanks a bunch

👍️0

OldAIMGuy 4 월 전

Hi MD,
Here's a little longer view:

This might also be a cyclical low here. But, most of 2024 has shown severe distribution of shares until about the last month. That, at least, seems to be flattening out.
Best wishes,
OAG

👍️0

Monksdream 4 월 전

CRSP trend since February remains bearish

👍️0

jondoeuk 5 월 전

Q2 results https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200100452.html

👍️0

lambchops 5 월 전

Hey Monk, Hopefully you bought some shares on Friday@ Sold at 10% discount!

LC

CRISPR!!!

Crispr added some $120 Vertical debit spreads in 2026

$CRSP

👍️ 1

axelvento 8 월 전

I agree.....solid company$$$$$$$$

👍️0

Monksdream 8 월 전

It may take some time for CRSP returns to a $200 price tag
The same could be said for hundreds of other stocks that soared during Covid mania
Since then the stock has rallied from low points
With all that money the company has to do incredible things with its biotechnology the stock isn’t going to zero

👍️ 1

axelvento 8 월 전

Strong balance sheet with approximately $2.1 billion in cash, cash equivalents, and marketable securities as of March 31, 2024

https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000059.html

👍️0

jondoeuk 8 월 전

(OT): A new AI paper from Princeton and Stanford https://www.biorxiv.org/content/10.1101/2024.04.25.591003v2.full

CRISPR-GPT demonstrated a marked improvement in gene-editing experiments, increasing the accuracy of target gene modifications by up to 30% compared to conventional methods. In validation tests, it achieved a specificity rate exceeding 95%, with a significant reduction in off-targets. The system also reduced the time required to design and plan experiments by approximately 40%, streamlining the workflow for researchers.

👍️0

jondoeuk 8 월 전

Business Update and Q1 Financial Results https://uk.finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000300.html

👍️0

jondoeuk 8 월 전

Highlights (plus new programs utilising in vivo gene editing) https://finance.yahoo.com/news/crispr-therapeutics-highlights-asgct-oral-110000066.html

👍️0

jondoeuk 9 월 전

https://www.globenewswire.com/news-release/2024/04/22/2867236/0/en/CRISPR-Therapeutics-to-Present-Oral-Presentation-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-2024-Annual-Meeting.html

EDIT is also pursuing myocilin-related glaucoma https://www.globenewswire.com/news-release/2024/04/22/2867244/0/en/Editas-Medicine-to-Present-Pre-clinical-Data-Demonstrating-Progression-of-in-vivo-Medicines-Pipeline-at-the-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html

👍️0

OldAIMGuy 9 월 전

StockCharts 3 year history with 20% ZigZag reversals................

CRSP seems to be suffering from lack of 'sponsorship' in that the stock has not shown "accumulation" trend along with the price rally since last year's October Low. There's been volume, but not accumulation bias.

Best wishes,
OAG

👍️0

OldAIMGuy 9 월 전

Hi MD,
CRSP is now down around 1/3 from its February high. The price is where I usually start to accumulate more shares.

Best wishes,
OAG

Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-american-society-120000624.html

👍️0

Monksdream 11 월 전

CRSP new 52 week high

👍️0

Monksdream 11 월 전

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

👍️0

Monksdream 11 월 전

CRSP new 52 week high

👍️ 1

Monksdream 11 월 전

CRSP new 52 week high

👍️ 1

jondoeuk 11 월 전

They entered into an investment agreement for the sale of ~$280 million of its shares to a select group of institutional investors in a registered direct offering, at $71.5 apiece. The financing is being led by EcoR1 Capital and SR One with participation from existing investors and a healthcare specialist investor https://finance.yahoo.com/news/crispr-therapeutics-announces-280-million-133000932.html

👍️0

jondoeuk 11 월 전

EU approval https://finance.yahoo.com/news/european-commission-approves-first-crispr-065900771.html

👍️ 1

Monksdream 11 월 전

Didn’t tank like BLUE
Recovered

More analysis from Nanolyze

👍️0

Monksdream 11 월 전

So there has been some discussion since my last post
More in this podcast

🌈 1 🍆 1

jondoeuk 1 년 전

Around two months ahead of expectations https://www.globenewswire.com/news-release/2024/01/16/2810298/0/en/CRISPR-Therapeutics-Announces-U-S-Food-and-Drug-Administration-FDA-Approval-of-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Transfusion-Dependent-Beta-Thalassemia.html

👍️ 1

jondoeuk 1 년 전

Strategic Priorities and 2024 Outlook https://finance.yahoo.com/news/crispr-therapeutics-highlights-strategic-priorities-120000043.html

👍️0

jondoeuk 1 년 전

Webcast link https://jpmorgan.metameetings.net/events/healthcare24/sessions/49607-crispr-therapeutics-inc/webcast/general_signin?gpu_only=true&kiosk=true

👍️ 1

jondoeuk 1 년 전

Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-42nd-annual-133000024.html

👍️0

JJ8 1 년 전

Good morning OAG,

Surprising and interesting. Share price sudden "jack-rabbit" moves in quick price reversals. The technical picture for today changed from positive breakout yesterday to "High Pole Warning" with sudden drop in price. Apparently the dominating group of participants seem to dictate this pace a bit unusual and different from other stocks. Yet it offers opportunity for profit once one has a good plan and strategy.

Good you have a plan and strategy for your preferred limits and ranges for your trading. Let's see how it goes. Have fun & GLTY

👍️ 1

OldAIMGuy 1 년 전

Good morning JJ8,

It needs to crest $85 or better to get me interested in reducing my share inventory. A drop to $57 will trigger an addition of 12% to share count.

I'd like to see it crest $72 and maintain that price right now.

Best wishes,
OAG

👍️0

JJ8 1 년 전

CRSP share price Double Top Breakout today on 19-Dec-2023. Happy Holidays & GLTA

👍️0

Monksdream 1 년 전

Oscar Wilde once observed that a cynic knows the price of everything and the value of nothing

👍️0

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

CRISPR Therapeutics AG (CRSP)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

CRSP 뉴스

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

Form 4 - Statement of changes in beneficial ownership of securities

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Form 4 - Statement of changes in beneficial ownership of securities

CRSP Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

CRISPR Therapeutics AG (CRSP) 뉴스

CRISPR Therapeutics AG (CRSP)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

CRSP 뉴스

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

Form 4 - Statement of changes in beneficial ownership of securities

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Form 4 - Statement of changes in beneficial ownership of securities

CRSP Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기